Stay updated with breaking news from Astrazeneca Soliris. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Samsung Bioepis, a biosimilar developer under Samsung Group, said Monday that the company's rare blood disease treatment, Epysqli, has won marketing authorization from South Korea's medicine authorities. Epysqli, a biosimilar close to AstraZeneca's Soliris (eculizumab), is a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare disease where red blood cells prematurely break apa...
FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two infused AstraZeneca drugs, Novartis’s pill is well-positioned to take market share from those blockbuster products.
The industry awaits a number of readouts and approvals for drugs that address market gaps and enrich treatment landscapes — with huge sales potential to boot.
In this article, we discuss the 11 safe healthcare stocks for a retirement stock portfolio.